Webinar Series 2019: Next-generation sequencing for DR-TB
Next-generation sequencing (NGS) has great potential as a method for rapidly diagnosing drug-resistant tuberculosis (DR-TB) in diverse clinical reference laboratory settings worldwide. The NGS approach overcomes many of the significant challenges associated with conventional phenotypic testing as well as the limitations of other less comprehensive molecular tests by providing rapid, detailed sequence information for multiple gene regions or whole genomes of interest. However, the uptake of these technologies for DR-TB diagnosis has been hindered by concerns regarding costs, integration into existing laboratory workflows, technical training and skill requirements for utilization of the technology, and the need for expert guidance regarding the management and clinical interpretation of sequencing data.
News and events
In settings where laboratory testing has been traditionally organized by disease programme, the introduction of multidisease testing devices brings new opportunities for collaboration and integration, which can provide significant system efficiencies and cost savings, increase patient access, and ultimately improve quality of care.
A framework of indicators and targets has been launched measuring programmes’ capacity to detect TB using new diagnostics, provide universal DST, and ensure the quality of testing under the End TB Strategy.
Rapid diagnostic test and shorter, cheaper treatment signal new hope for multidrug-resistant tuberculosis patients
New WHO recommendations aim to speed up detection and improve treatment outcomes for multidrug resistant tuberculosis (MDR-TB) through use of a novel rapid diagnostic test and a shorter, cheaper treatment regimen.
Tests based on the detection of mycobacterial lipoarabinomannan (LAM) antigen in urine have emerged as potential point-of-care tests for TB. WHO has issued recommendations on the use of a lateral flow LAM assay for the diagnosis and screening of active TB in people living with HIV.
Bridging the growing gap between diagnosis and treatment in multidrug-resistant tuberculosis (MDR-TB)
An unprecedented scale-up in test development and laboratory strengthening has been seen since 2009, when the World Health Assembly called for universal access to tuberculosis (TB) drug susceptibility testing (DST) and treatment of all patients with drug-resistant disease.
- Consensus Meeting Report: Development of a Target Product Profile (TPP) and a framework for evaluation for a test for predicting progression from tuberculosis infection to active disease
- Technical Expert Group Meeting Report: Commercial products for preserving clinical specimens for the diagnosis of tuberculosis.
- High-priority target product profiles for new tuberculosis diagnostics
- WHO policies on diagnostics and laboratory strengthening
- WHO Framework of indicators and targets for laboratory strengthening
- Framework for implementing TB diagnostics
Policy guidance on the molecular second-line line-probe assay